Cardiac tumours originate within the heart tissues or spread from elsewhere in the body. They disrupt normal heart mechanics by obstructing blood flow, damaging valves, or invading the myocardium. These growths can be primary, starting directly in the heart, or secondary, arriving from distant organs via metastasis. Primary cardiac tumours are exceptionally rare in clinical practice, while secondary tumours appear much more frequently during autopsies of cancer patients.
Most primary cardiac growths are non-cancerous, yet they still cause serious hemodynamic instability.
Secondary cardiac tumours outnumber primary ones by a significant margin. Cancers spread to the heart via the bloodstream, the lymphatic system, direct extension from neighboring structures, or through the inferior vena cava. Common primary cancer sources include lung cancer, breast cancer, malignant melanoma, and renal cell carcinoma. These metastatic lesions frequently affect the pericardium, causing pericardial effusions or cardiac tamponade.
Symptoms of cardiac tumours mimic other common cardiovascular diseases, leading to frequent diagnostic delays. Manifestations depend entirely on the tumour's exact location, size, and mobility rather than its histological type.
Confirming a cardiac mass requires specialized imaging modalities. Transthoracic echocardiography serves as the primary initial screening tool because it provides rapid visualization of intracardiac structures. Transesophageal echocardiography offers superior detail for small or posteriorly located atrial masses. Cardiac magnetic resonance imaging and computed tomography scans help define tissue characteristics, vascularity, and the exact borders of the tumour before surgical planning.
Treatment strategies vary drastically between benign and malignant pathologies. Surgical resection remains the definitive treatment for primary benign tumours like myxomas to eliminate the risk of sudden embolization or obstruction. Malignant primary tumours carry a poor prognosis, requiring a combination of surgical debulking, chemotherapy, and radiation therapy. Secondary metastatic tumours are generally managed with palliative systemic therapy, as complete surgical cure is rarely possible.
Nurses caring for patients recovering from cardiac tumour resection must monitor hemodynamics closely in an intensive care setting. Continuous cardiac telemetry is vital to detect post-operative arrhythmias resulting from surgical manipulation of the myocardium. Nurses assess peripheral pulses and neurological status frequently to catch early signs of thromboembolic events. Pain control, respiratory hygiene, and careful management of chest tube drainage complete the immediate post-operative recovery phase.
Prognosis for cardiac tumour patients depends heavily on the histological diagnosis and timely intervention. Benign tumours like myxomas carry an excellent long-term survival rate once completely resected, though rare recurrences do happen. Conversely, malignant primary tumours and metastatic lesions involve a grim outlook, with rapid disease progression and high mortality rates. Major complications include heart failure, malignant arrhythmias, systemic embolization, and sudden cardiac death.